Dergiler / Şişli Etfal Hastanesi Tıp Bülteni / 2019 / Cilt: 53 - Sayı: 3

Surgical Treatment of Primary Hyperparathyroidism: Which Therapy to Whom?

Sayfa
201–214
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

In this study, we aimed to determine the type of surgical treatment and pHPT patients suitable for the surgical treatment.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Primary hyperparathyroidism (pHPT) is characterized by an increase in the levels of PTH and Ca, or one of these (Ca, PTH) as a result of a dysregulation of calcium (Ca) metabolism due to inappropriate excess parathyroid hormone (PTH) autonomously produced from one or more than one parathyroid glands.
📊
Temel Bulgular & Veri:Ninety to 95% of pHPT is a sporadic type, which is not associated with the familial history and other endocrine organ tumors, and 5-10% of it is hereditary.
💡
Sonuç & Katkı:In this study, we aimed to determine the type of surgical treatment and pHPT patients suitable for the surgical treatment.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Primary hyperparathyroidism (pHPT) is characterized by an increase in the levels of PTH and Ca, or one of these (Ca, PTH) as a result of a dysregulation of calcium (Ca) metabolism due to inappropriate excess parathyroid hormone (PTH) autonomously produced from one or more than one parathyroid glands. Ninety to 95% of pHPT is a sporadic type, which is not associated with the familial history and other endocrine organ tumors, and 5-10% of it is hereditary. While 80-85% of pHPT arises from a single parathyroid adenoma, 4-5% is caused by a double adenoma, 10-15% by multigland hyperplasia and less than 1% by parathyroid cancer. The diagnosis of pHPT is reached biochemically. The only curative treatment of pHPT is surgery. The choice of surgery in pHPT may vary depending on whether the patient has hereditary HPT or thyroid disease requiring surgical treatment, preoperative localization studies and the findings in these studies, the possibilities of using intraoperative PTH and the preference of the surgeon. The preoperatively determined surgical strategy can be revised according to intraoperative findings in case of need to achieve excellent results. The two main approaches in the surgical treatment of pHPT are BNE (bilateral neck exploration) and MIP (minimal invasive parathyroidectomy). Although BNE is a consistently valid option that has excellent results in the surgical treatment of pHPT and is considered the gold standard, MIP is the ideal approach in selected patients with clinically and radiologically considered a single-gland disease. Negative imaging is not a contraindication for parathyroid surgery and is not a criterion for the presence or absence of surgical indication. Although both methods are safe and effective in the surgical treatment of sporadic pHPT, there is still controversy regarding the effectiveness of both methods. Surgical intervention should establish the risk-benefit balance well, minimize the risk of persistent and recurrent disease and provide the highest cure rate without increasing the risk of complications. Complication rates are higher in the secondary surgery, thus in secondary procedures, selective surgery should be performed under guidance of an imaging modality. The surgical strategy should be determined to achieve maximum cure with minimum dissection and minimal morbidity. In this study, we aimed to determine the type of surgical treatment and pHPT patients suitable for the surgical treatment.

🔖

Bu Makaleye Atıf Yap

AYGÜN, N., ULUDAĞ, M. (2019). Surgical Treatment of Primary Hyperparathyroidism: Which Therapy to Whom?. Şişli Etfal Hastanesi Tıp Bülteni, Cilt: 53 - Sayı: 3, 201–214. https://ajindex.com/articles/364001

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (17)

  1. Walker MD, Bilezikian JP. Primary hyperparathyroidism: recent advances. Curr Opin Rheumatol 2018;30:427–39
  2. Uludag M, Aygun N. Primary hyperparathyroidism: Current situation in the clinical and biochemical presentation. Med Bull Sisli Etfal Hosp 2016;50:171–80
  3. Madkhali T, Alhefdhi A, Chen H, Elfenbein D. Primary hyperparathyroidism. Ulus Cerrahi Derg 2016;32:58–66
  4. Mallick R, Chen H. Diagnosis and Management of Hyperparathyroidism. Adv Surg 2018;52:137–53
  5. Yeh MW, Ituarte PH, Zhou HC, Nishimoto S, Liu IL, Harari A, et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab 2013;98:1122–9
  6. Press DM, Siperstein AE, Berber E, Shin JJ, Metzger R, Monteiro R, et al. The prevalence of undiagnosed and unrecognized primary hyperparathyroidism: a population-based analysis from the electronic medical record. Surgery 2013;154:1232–7
  7. Iacobone M, Carnaille B, Palazzo FF, Vriens M. Hereditary hyperparathyroidism--a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch Surg 2015;400:867–86
  8. Felger EA, Kandil E. Primary hyperparathyroidism. Otolaryngol Clin North Am 2010;43:417–32
  9. Eastell R, Brandi ML, Costa AG, D'Amour P, Shoback DM, Thakker RV. Diagnosis of asymptomatic primary hyperparathyroidism: pro ceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014;99:3570–9
  10. Uludağ M. Normocalcemic hyperparathyroidism: A new clinical type of primary hyperparathyroidism. Med Bull Sisli Etfal Hosp 2014;48:264–73
  11. Machado NN, Wilhelm SM. Diagnosis and Evaluation of Primary Hyperparathyroidism. Surg Clin North Am 2019;99:649–66
  12. Callender GG, Udelsman R. Surgery for primary hyperparathyroidism. Cancer 2014;120:3602–16
  13. Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 2014;99:3561–9
  14. Wu JX, Yeh MW. Asymptomatic Primary Hyperparathyroidism: Diagnostic Pitfalls and Surgical Intervention. Surg Oncol Clin N Am 2016;25:77–90
  15. Mandl F. Versuch bei Ostitis fibrosa generalisata mittels Exstirpation eines Epithelkörperchen Tumors.Wien Klin Wehnschr 1925;50:1343
  16. Albright F, Aub JC, Bauer W. A Common And Polymorphic Condition As Illustrated By Seventeen Proved Cases From One Clinic. JAMA 1934;102:1276–87
  17. Churchill ED, Cope O. The